News Releases

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by Seagen Portfolio reprioritization and extension of cash runway into 2026
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to extend the cash runway further into 2026 UTRECHT, The Netherlands, and PHILADELPHIA, June 14, 2023
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA Strong balance sheet expected to provide cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, June 08, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies. In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of novel bispecific antibody-based gamma
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced
LAVA Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the annual
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma Initial clinical data for LAVA-1207, a Phase 1/2a
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of